At BioM's 12th BioAngels Pitch Day on December 6, promising start-ups again met potential investors. Eight selected start-up teams had the opportunity to present their business idea in front of venture capital investors and business angels from the Life Science sector. Once again, the great potential of the Bavarian start-up scene with innovative ideas in the fields of drug development, next generation diagnostics, digital health and industrial biotech was demonstrated.
At the exclusive matchmaking event, promising pre-seed teams and start-ups again had the opportunity to convince prospective funders with an investment focus on life sciences and healthtech of their technology and business model - in just 12 minutes, with scientific data and a sound business strategy.
The project ideas were diverse. With the aim of successfully acquiring funding, new solutions in diagnostics were presented alongside the development of innovative drugs for the treatment of tumors, infectious and autoimmune diseases as well as depression.
BioM prepared the founders for their virtual pitch in a separate training session. The aim was to present the business model convincingly and in a compact form. Thus, the teams were well equipped for the in-depth questions of the invited investors after the pitches.
The subsequent networking lunch provided an additional opportunity for further personal exchange.
Dr. Valentin Bruttel from AIM Biologics was delighted to have the opportunity to present at the BioAngels Pitch Day. With his business idea, his team already won the m4 Award pre-seed competition in 2017. Now his team is looking for investors for seed funding.
"We are in the spin-off phase with our project. The BioM BioAngels Pitch Day is therefore the perfect event for us to get in touch with suitable investors. With the competent preparation by BioM, we were able to present our start-up convincingly. The interest of the investors has sustainably confirmed us in our plan to develop low side-effect precision therapeutics against autoimmune diseases."
Co-founder Prof. Wischhusen has already successfully founded the start-up Catalym, which has just raised a series C financing of 50 million Euros. Now the team wants to enter the field of immunomodulation for autoimmune diseases with AIM Biologicals.
Dr. Claus Josef Schulte of Carma Fund Management GmbH also commented positively: "We are always looking for innovations that create added value in the healthcare sector. The selection of the start-up teams by BioM was again excellent and shows the great potential of the Bavarian biotech start-up scene."
As part of its virtual start-up incubator inQlab, the BioM matchmaking event helps young bioentrepreneurs find the right contacts with potential investors in the biomedical field.
The next BioAngels Pitch Day will take place in the second quarter of 2023. Teams that are looking for capital and would like to present their business idea in this setting can apply to Dr. Petra Burgstaller or Christina Enke-Stolle: burgstaller@bio-m.org or enke-stolle@bio-m.org.